Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
65.50    -0.50 (-0.76%)
Bid:
65.00
Ask:
66.00
Spread: 1.00 (1.538%)
Market Cap: £79.80m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

Director/PDMR Shareholding

4 Jun 2026 07:00

RNS Number : 9188G
Venture Life Group PLC
04 June 2026
 

4 June 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director/PDMR Shareholding

Venture Life (AIM: VLG), a recognised leader in proactive longevity, health innovation and global commercialisation within the global consumer healthcare sector, announces that Paul McGreevy, Non-Executive Chairman, purchased 88,273 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") on 3 June 2026 at a volume-weighted average price of 62.3 pence per Ordinary Share.

Following the purchase, Mr McGreevy beneficially holds 1,052,098 Ordinary Shares representing approximately 0.82 per cent. of the Company's issued share capital.

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker)

 

+44 (0) 20 7720 0500

Stephen Keys / George Lawson / Joe Smith (Corporate Finance)

Michael Johnson (Sales)

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation:

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Paul McGreevy

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Venture Life Group plc

b)

 

LEI

 

213800S8CZUPLAB2KC70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

Ordinary Shares of 0.3p each in Venture Life Group plc

 

 

 

GB00BFPM8908

b)

 

Nature of the transaction

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price

Volume

61.6 pence

8,105

61.9 pence

8,066

61.9 pence

8,066

63.8 pence

15,663

62.0 pence

48,373

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

88,273 Ordinary Shares purchased at a volume-weighted average price of 62.3 pence.

 

 

e)

 

Date of the transaction

 

3 June 2026

f)

 

Place of the transaction

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFFFVLRAIVIIR
Date   Source Headline
17th May 20227:00 amRNSDirectorate Changes
17th May 20227:00 amRNSFinal Results
10th May 202211:31 amRNSExercise of Share Options & Voting Rights
19th Apr 20227:00 amRNSReporting Update
23rd Mar 20223:00 pmRNSAnnouncement re: Full year results
22nd Feb 20227:00 amRNSGrant of Options and PDMR Dealing
21st Feb 20227:00 amRNSResults - clinical trial led by Cardiff University
31st Jan 20224:41 pmRNSSecond Price Monitoring Extn
31st Jan 20224:37 pmRNSPrice Monitoring Extension
31st Jan 20222:06 pmRNSSecond Price Monitoring Extn
31st Jan 20222:01 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSTrading Statement
24th Jan 20222:06 pmRNSSecond Price Monitoring Extn
24th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSBusiness Update
29th Dec 202112:34 pmRNSDirector/PDMR Shareholding
20th Dec 20214:13 pmRNSDirectorate Change
14th Dec 202111:05 amRNSSecond Price Monitoring Extn
14th Dec 202111:01 amRNSPrice Monitoring Extension
3rd Dec 20214:22 pmRNSDirector/PDMR Shareholding
1st Dec 20219:06 amRNSSecond Price Monitoring Extn
1st Dec 20219:00 amRNSPrice Monitoring Extension
1st Dec 20217:00 amRNSTrading Update & Board Changes
1st Nov 20212:00 pmRNSPrice Monitoring Extension
1st Nov 20218:44 amRNSHolding(s) in Company
1st Nov 20218:43 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSHolding(s) in Company
11th Oct 20212:41 pmRNSHolding(s) in Company
23rd Sep 20219:05 amRNSSecond Price Monitoring Extn
23rd Sep 20219:00 amRNSPrice Monitoring Extension
23rd Sep 20217:00 amRNSHalf-year Report
7th Sep 20211:54 pmRNSHolding(s) in Company
13th Aug 20219:05 amRNSSecond Price Monitoring Extn
13th Aug 20219:00 amRNSPrice Monitoring Extension
13th Aug 20217:00 amRNSTrading Update and Progress on recent Acquisitions
6th Aug 20217:00 amRNSAcquisition of Oncology Support Product Assets
21st Jun 20217:00 amRNSRevolving Credit Facility
7th Jun 20217:00 amRNSAcquisition of BBI Healthcare Limited
20th May 20212:29 pmRNSResult of AGM
14th Apr 20214:19 pmRNSHolding(s) in Company
25th Mar 20212:19 pmRNSConfirmation of AGM Date
25th Mar 20217:00 amRNSFinal Results
25th Feb 20217:00 amRNSInvestor Presentation
1st Feb 20217:00 amRNSTrading Update & Notice of Results
14th Dec 20202:07 pmRNSIssue of Equity
11th Dec 20207:27 amRNSHolding(s) in Company
10th Dec 20204:45 pmRNSHolding(s) in Company
10th Dec 20204:41 pmRNSHolding(s) in Company
10th Dec 20202:42 pmRNSHolding(s) in Company
10th Dec 20201:45 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.